"Drug Combinations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
| Descriptor ID |
D004338
|
| MeSH Number(s) |
D26.310
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Combinations".
Below are MeSH descriptors whose meaning is more specific than "Drug Combinations".
- Drug Combinations
- Adapalene, Benzoyl Peroxide Drug Combination
- Albuterol, Ipratropium Drug Combination
- Aminophylline
- Amlodipine Besylate, Olmesartan Medoxomil Drug Combination
- Amlodipine, Valsartan Drug Combination
- Aspirin, Dipyridamole Drug Combination
- Biphasic Insulins
- Brimonidine Tartrate, Timolol Maleate Drug Combination
- Budesonide, Formoterol Fumarate Drug Combination
- Buprenorphine, Naloxone Drug Combination
- Contraceptives, Oral, Combined
- Dimenhydrinate
- Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Emtricitabine, Rilpivirine, Tenofovir Drug Combination
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Ezetimibe, Simvastatin Drug Combination
- Fluticasone-Salmeterol Drug Combination
- Mometasone Furoate, Formoterol Fumarate Drug Combination
- Multi-Ingredient Cold, Flu, and Allergy Medications
- Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
- Trimethoprim, Sulfamethoxazole Drug Combination
This graph shows the total number of publications written about "Drug Combinations" by people in this website by year, and whether "Drug Combinations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Combinations" by people in Profiles.
-
The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis. ESC Heart Fail. 2025 Apr; 12(2):998-1012.
-
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
-
In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924.
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
-
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
-
Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
-
Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
-
New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).
-
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
-
Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.